The FDA has approved the CD19+ B-cell targeted therapy inebilizumab-cdon (Uplizna, Amgen) for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine ...

Please provide your email address to receive an email when new articles are posted on . FDA approves inebilizumab-cdon for adults with anti-acetylcholine receptor and anti-muscle specific tyrosine ...

Emmett School District Curriculum & Instruction Coordinator Ramey Uriarte introduced a three-year “Math Improvement Plan” to the Emmett School Board Trustees at a meeting on Monday, Oct. 13, aiming to ...

Generalized anxiety disorder affects 1 in 20 U.S. adults. Those with serious symptoms may isolate themselves to the point they rarely leave their home and are unable to work and build meaningful ...

For generations of U.S. schoolchildren, phrases like "shuttle run" and "sit-and-reach" likely conjure vivid memories of what was once a staple of American physical education: the Presidential Fitness ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing ...

Stress, infections, and corticosteroid withdrawal are known triggers of generalized pustular psoriasis (GPP). However, doctors cannot attribute every GPP flare to a specific cause. Psoriasis is an ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to disease ...